DEF: Foghorn Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Foghorn Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on the election of directors and ratification of the company's independent accounting firm.

Summary

• Foghorn Therapeutics Inc. will hold its 2025 Annual Meeting of Stockholders on June 17, 2025, at 9 a.m. Eastern Time, as a virtual-only meeting.
• Stockholders must register at www.proxydocs.com/FHTX to attend the meeting.
• The meeting will address the election of Stuart Duty, Neil J. Gallagher, M.D., Ph.D., Adrian Gottschalk, and Ian F. Smith as Class II directors for a three-year term.
• Stockholders will also vote to ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting for the director nominees and for the ratification of Deloitte & Touche LLP.
• The record date for determining stockholders entitled to vote is April 28, 2025.
• As of April 28, 2025, there were 55,721,340 shares of common stock outstanding and entitled to vote.
• The proxy statement and the Annual Report on Form 10-K for the year ended December 31, 2024, are available at www.proxydocs.com/FHTX.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions. The Board's recommendations are clearly stated, and the overall sentiment is professional and informative.

Positives

• The company is providing stockholders with multiple avenues to vote, including online, by phone, and by mail.
• The Board of Directors is actively engaged in risk oversight, with committees dedicated to specific areas of risk management.
• The company has adopted a clawback policy to recover compensation in the event of financial restatements due to material noncompliance.
• The company has a written code of business conduct and ethics applicable to all directors, officers, and employees.
• The company has an insider trading policy to promote compliance with insider trading laws.

Negatives

• The company is an emerging growth company and is relying on exemptions from certain disclosure requirements.
• The division of the Board of Directors into three classes with staggered three-year terms may delay or prevent a change of management or a change in control.

Risks

• The proxy statement notes that the division of the Board of Directors into three classes with staggered three-year terms may delay or prevent a change of management or a change in control.
• The company's insider trading policy expressly prohibits short sales, purchases or sales of puts, calls or other derivative securities of the company, engaging in any other hedging transaction with respect to the company's securities, using the company's securities in a margin account and pledging the company securities as collateral, in each case by our directors, officers, employees and certain contractors and consultants.

Future Outlook

The document outlines the proposals to be voted on at the upcoming annual meeting, including the election of directors and ratification of the independent accounting firm. It does not contain specific forward-looking statements about the company's financial performance or business prospects beyond the standard legal disclaimers.

Management Comments

• The Board of Directors recommends that you vote for each nominee for Class II director (Proposal No. 1) and for ratification of the proposed independent registered public accounting firm (Proposal No. 2).
• Thank you for your ongoing support of and interest in Foghorn Therapeutics Inc.

Industry Context

This proxy statement is a standard document for publicly traded companies, providing stockholders with information necessary to make informed decisions regarding the election of directors and other corporate governance matters. The proposals are typical for an annual meeting and reflect the company's ongoing operations and governance structure.

Comparison to Industry Standards

• The structure and content of this proxy statement are consistent with industry standards for publicly traded companies in the United States.
• The director compensation policy is in line with those of other biotechnology companies of similar size and stage of development.
• The use of a virtual-only annual meeting is becoming increasingly common among public companies, offering cost savings and increased accessibility for stockholders.

Management Changes

Related Party Transactions

• In October 2015, we entered into a consulting agreement with Cigall Kadoch, Ph.D., our academic co-founder, former director and holder of 6.57% of our Common Stock, pursuant to which Dr. Kadoch provides advisory services related to the manufacturing and sale of products and services related to chromatin remodeling.
• On December 10, 2021, we entered into a strategic collaboration (the Lilly Collaboration Agreement) with Eli Lilly and Company (Lilly).
• On January 16, 2024, the Company appointed Stephen J. DiPalma, a managing director at Danforth Advisors, LLC (Danforth), as Treasurer and interim Chief Financial Officer, a position he held until April 16, 2024.

Stakeholder Impact

• The election of directors and ratification of the accounting firm are important decisions that impact the company's governance and financial oversight, which can affect shareholder value.
• Executive compensation decisions impact the alignment of management's interests with those of shareholders.
• The company's code of ethics and insider trading policy promote ethical behavior and compliance with regulations, which benefits all stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• Stockholders who wish to attend the virtual-only Annual Meeting must register at www.proxydocs.com/FHTX.
• The Board of Directors will consider the results of the votes at the Annual Meeting and take appropriate action.

Key Dates

Keywords

proxy statement, annual meeting, directors, stockholders, governance, compensation, Deloitte & Touche, voting, Foghorn Therapeutics, election